Health Biotech
Innovative biotech solutions enhancing brain health and delaying aging through advanced carnitine research.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
CNY222m | Series B | ||
| Total Funding | 000k | ||
Haosi Biotech is a pioneering biotechnology company specializing in the research and development of carnitine-based solutions aimed at enhancing brain health and delaying the aging process. The company operates in the healthcare and biotechnology market, serving clients ranging from medical institutions to research organizations. Haosi Biotech's business model revolves around the development, production, and distribution of carnitine products, which are synthesized from lysine and methionine and play a crucial role in brain cell metabolism. The company generates revenue through the sale of these specialized products and through partnerships with healthcare providers and research institutions. In 2020, Haosi Biotech secured hundreds of millions of yuan in Series B financing and was recognized as one of the Top 100 Chinese Innovation and Growth Enterprises and one of the Top 80 Chinese Healthcare Innovation Enterprises. The company also received accolades from the Beijing Municipal Science and Technology Commission for its innovative projects.
Keywords: carnitine, brain health, aging, biotechnology, healthcare, research, innovation, financing, metabolism, China.